Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ADC Therapeutics (ADCT) Gross Margin (2020 - 2026)

ADC Therapeutics has reported Gross Margin over the past 7 years, most recently at 36.56% for Q1 2026.

  • Quarterly results put Gross Margin at 36.56% for Q1 2026, up 14762.0% from a year ago — trailing twelve months through Mar 2026 was 26.04% (up 60.0% YoY), and the annual figure for FY2022 was 2181331.87%, down 218142734.0%.
  • Gross Margin reached 36.56% in Q1 2026 per ADCT's latest filing, up from 32.14% in the prior quarter.
  • Across five years, Gross Margin topped out at 99.3% in Q4 2022 and bottomed at 111.06% in Q1 2025.
  • Median Gross Margin over the past 5 years was 38.96% (2024), compared with a mean of 44.94%.
  • The largest annual shift saw Gross Margin soared 452674827bps in 2022 before it crashed -14797bps in 2025.
  • Over 5 years, Gross Margin stood at 99.3% in 2022, then crashed by -95bps to 5.26% in 2023, then skyrocketed by 674bps to 40.76% in 2024, then decreased by -21bps to 32.14% in 2025, then grew by 14bps to 36.56% in 2026.
  • Business Quant data shows Gross Margin for ADCT at 36.56% in Q1 2026, 32.14% in Q3 2025, and 46.14% in Q2 2025.